Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC) - Trial NCT05955209
Access comprehensive clinical trial information for NCT05955209 through Pure Global AI's free database. This Phase 2 trial is sponsored by Peking University Cancer Hospital & Institute and is currently Not yet recruiting. The study focuses on Metastatic Castration-resistant Prostate Cancer. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Peking University Cancer Hospital & Institute
Timeline & Enrollment
Phase 2
Aug 01, 2023
Aug 01, 2025
Primary Outcome
PSA response rate
Summary
This is a single-arm, open, single-center clinical study to evaluate the efficacy and safety
 of RC48-ADC in patients with mCRPC who have progressed after NHT. A total of 40 patients with
 mCRPC with immunohistochemically confirmed HER2 expression who had progressed after treatment
 with at least one novel endocrine therapy will be included in this study.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05955209
Non-Device Trial